Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
Developing robust, scalable peptide processes through route optimization, impurity control, and manufacturing-focused process design.
A laboratory synthesis can confirm that a sequence is accessible. It does not automatically show that the route will remain efficient, reproducible, or economical at larger scale. Aggregation, incomplete coupling, cyclization, sequence-related impurities, purification losses, and isolation behaviour may become more visible as material requirements increase.
Peptide process development therefore starts with the intended scale and end use in mind. We evaluate synthesis strategy, impurity profile, analytical requirements, process robustness, and manufacturing fit together to build a process that can evolve from development through commercialization.
From route selection to scale-up readiness, each stage of development contributes to building a robust and manufacturable peptide process.
Assess the sequence, building blocks, protecting-group strategy, synthesis options, and practical route constraints.
Discuss sequence complexity, current route, impurity challenges, target quality, and future material requirements.
Quick answers to help you better understand our CDMO capabilities and approach.
Still have Questions? Contact UsPeptide process development is the systematic work required to turn a synthesis route into a reproducible and scalable manufacturing process. It includes route design, optimization, impurity control, analytical support, stability assessment, and scale-up planning.
Potential challenges include aggregation, incomplete reactions, cyclization complexity, sequence-related impurities, purification limitations, and changes in process behaviour at larger scale.
Neuland supports SPPS, LPPS, and hybrid synthesis approaches. Selection depends on peptide length, structure, scale, and manufacturing objectives.
Preparing a peptide process for manufacturing involves establishing critical process parameters (CPPs), defining critical quality attributes (CQAs), implementing impurity control strategies, assessing process safety, and evaluating manufacturing readiness to support successful scale-up and transfer.
Choose solid-phase, liquid-phase, or a combined route based on sequence length, structural complexity, scale, and process performance.
Refine reaction and work-up conditions to improve yield, reproducibility, robustness, and manufacturing practicality.
Investigate process-related impurities, residual solvents, degradation products, and potential genotoxic impurities, including trace-level risks where required.
Generate data that informs storage conditions, shelf life, degradation pathways, and stability-indicating methods.
Define critical process parameters, critical quality attributes, safety considerations, and transfer requirements before manufacturing execution.
